Werewolf Therapeutics (NASDAQ:HOWL) Stock Rating Lowered by Wedbush

Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by Wedbush from an “outperform” rating to a “neutral” rating in a note issued to investors on Friday, MarketBeat.com reports. They presently have a $1.00 target price on the stock. Wedbush’s price target would indicate a potential upside of 45.60% from the stock’s current price.

Several other equities research analysts have also recently commented on HOWL. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. HC Wainwright dropped their price target on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Friday. JMP Securities decreased their price objective on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. Bank of America dropped their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Finally, Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research note on Wednesday, November 12th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Werewolf Therapeutics presently has a consensus rating of “Hold” and an average target price of $3.75.

Werewolf Therapeutics Price Performance

Shares of HOWL opened at $0.69 on Friday. Werewolf Therapeutics has a twelve month low of $0.56 and a twelve month high of $2.38. The company has a market capitalization of $33.34 million, a P/E ratio of -0.42 and a beta of 0.74. The firm has a 50 day moving average of $1.18 and a 200 day moving average of $1.31. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03. As a group, equities research analysts anticipate that Werewolf Therapeutics will post -1.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Werewolf Therapeutics

In related news, major shareholder Ansbert Gadicke sold 140,488 shares of the firm’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $1.22, for a total value of $171,395.36. Following the transaction, the insider directly owned 6,007,122 shares of the company’s stock, valued at approximately $7,328,688.84. This trade represents a 2.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Bioventures 2014 L.P. Mpm sold 140,488 shares of Werewolf Therapeutics stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $1.22, for a total value of $171,395.36. Following the transaction, the insider owned 6,007,122 shares in the company, valued at $7,328,688.84. This trade represents a 2.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 5,337,021 shares of company stock worth $6,108,970 in the last quarter. Corporate insiders own 23.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new position in shares of Werewolf Therapeutics during the 2nd quarter valued at about $409,000. Citadel Advisors LLC bought a new stake in Werewolf Therapeutics during the 3rd quarter worth approximately $304,000. Vanguard Group Inc. lifted its holdings in Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Marshall Wace LLP purchased a new position in Werewolf Therapeutics during the second quarter valued at approximately $113,000. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Werewolf Therapeutics in the second quarter worth approximately $92,000. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.